title: Preparation and in vitro evaluation of a pluronic lecithin organogel containing ricinoleic acid for transdermal delivery.
abstract: The present study deals with the preparation and in vitro evaluation of a Pluronic lecithin organogel gel containing ricinoleic acid for transdermal delivery. Blank Pluronic lecithin organogel gels were prepared using ricinoleic acid as the oil phase and characterized for pH, viscosity, gelation temperature, and microscopic structure. The optimized Pluronic lecithin organogel gel formulation was further evaluated using ketoprofen (10%) and dexamethasone (0.5%) as model drugs. The stability and in vitro permeability of ketoprofen and dexamethasone was evaluated and compared with the corresponding control formulation (Pluronic lecithin organogel gel made with isopropyl palmitate as the oil phase). The pH and viscosity of blank Pluronic lecithin organogel gel prepared with ricinoleic acid was comparable with the isopropyl palmitate Pluronic lecithin organogel gel. The thixotropic property of ricinoleic acid Pluronic lecithin organogel gel was found to be better than the control. Drug-loaded Pluronic lecithin organogel gels behaved in a similar manner and all formulations were found to be stable at 25 degrees C, 35 degrees C, and 40 degrees C for up to 35 days. The penetration profile of dexamethasone was similar from both the Pluronic lecithin organogel gels, while the permeability for ketoprofen from Pluronic lecithin organogel gel containing ricinoleic acid was found to be three times higher as compared to the control formulation.
authors.forename: Sai Hs
authors.initials: SH
authors.lastname: Boddu
authors.forename: Sindhu Prabha
authors.initials: SP
authors.lastname: Bonam
authors.forename: Yangjie
authors.initials: Y
authors.lastname: Wei
authors.forename: Kenneth
authors.initials: K
authors.lastname: Alexander
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism; D002417:Cattle; D002626:Chemistry, Pharmaceutical; D003907:Dexamethasone / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism; D004337:Drug Carriers; D004339:Drug Compounding; D005079:Excipients / Q000737:chemistry*; D005753:Gastric Mucosa / Q000378:metabolism; D005782:Gels; D006863:Hydrogen-Ion Concentration; D007660:Ketoprofen / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism; D054709:Lecithins / Q000737:chemistry*; D010539:Permeability; D020442:Poloxamer / Q000737:chemistry*; D012277:Ricinoleic Acids / Q000737:chemistry*; D012867:Skin / Q000378:metabolism; D012869:Skin Absorption; D012995:Solubility; D013552:Swine; D013678:Technology, Pharmaceutical / Q000379:methods; D013696:Temperature; D013997:Time Factors; D014783:Viscosity
chemical_list: D000893:Anti-Inflammatory Agents; D004337:Drug Carriers; D005079:Excipients; D005782:Gels; D054709:Lecithins; D012277:Ricinoleic Acids; D020442:Poloxamer; D003907:Dexamethasone; D007660:Ketoprofen; C030521:ricinoleic acid